Published online before print May 11, 2006, doi: 10.1161/01.RES.0000225952.61196.39
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Integrative Physiology |
Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling
From the Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Ohio.
Correspondence to Muhammad Ashraf, PhD, Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267-0529. E-mail muhammad.ashraf{at}uc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this study, we hypothesized that bone marrow stem cells (BMSCs) protect ischemic myocardium through paracrine effects that can be further augmented with preconditioning. In in vitro experiments, cell survival factors such as Akt and eNOS were significantly increased in BMSCs following anoxia. In the second series of experiments following coronary ligation in mice, left ventricles were randomly injected with the following: DMEM (G-1), BMSCs (G-2), and preconditioned BMSCs (G-3). Four days after myocardial infarction, BMSCs were observed within injured myocardium in G-2 and G-3. Apoptotic cardiomyocytes within periinfarct area were significantly reduced in G-3. Four weeks after myocardial infarction, smaller left ventricular (LV) dimension and increased LV ejection fraction were observed in G-3. Infarct area was significantly reduced in G-3. However, GFP+ cardiomyocytes were observed in low numbers within periinfarct area in G-2 and G-3. In conclusion, BMSCs secreted cell survival factors under ischemia, and they prevented apoptosis in cardiomyocytes adjacent to the infarcted area. Preconditioning of BMSCs enhanced their survival and ability to attenuate LV remodeling, which was attributable, in part, to paracrine effects.
Key Words: stem cells • paracrine effect • preconditioning • ischemia • remodeling
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Myocardial infarction (MI) leads to cardiomyocyte loss and scar formation in the infarcted area. The large transmural infarction is associated with ventricular remodeling after MI.1 Ventricular remodeling is characterized by changes in left ventricular (LV) geometry, mass, volume, and function, which include hypertrophy and cellular apoptosis of cardiomyocytes, in response to myocardial injury or alteration in load.2 Ventricular remodeling is also a major factor in the progression of heart failure, and the prognosis for survival is poor.
One approach proposed to reverse myocardial remodeling is regeneration of new cardiomyocytes. Recent reports have shown that bone marrow stem cells (BMSCs) have multilineage differentiation potential and potentially cross the lineage restriction to form various nonhematopoietic tissues including heart.3 Most studies on BMSC therapy in experimental animal heart models4–6 and patients with acute MI7–9 have shown an improvement in cardiac function, signifying the safety and feasibility of this approach. However, the mechanism of BMSC therapy is still controversial. BMSCs repair the ischemic myocardium primarily by angioblast-mediated vasculogenesis,10,11 prevention of apoptosis of native cardiomyocytes, or direct regeneration of the lost cardiomyocytes.
We, therefore, hypothesized that BMSCs protected ischemic myocardium through paracrine effects that could be further augmented with preconditioning.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
An expanded Materials and Methods section can be found in the online data supplement available at http://circres.ahajournals.org.
Coculture of BMSCs and Cardiomyocytes
Isolation and purification of BMSCs from C57B6 mice (Harlan, Indianapolis, Ind) were performed as described previously.12 All animals were treated in accordance with the Guidelines for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 85-23, Revised 1996). The details can be found in the online data supplement.
Detection of Cell Apoptosis: DNA Laddering and Annexin V Staining
For DNA laddering, after exposure to anoxia, 2x106 cells were suspended in PBS and homogenized in buffer containing proteinase K and RNase. After 15 minutes of incubation at 37°C, NaI solution was added. Cell lysates were incubated at 50°C for 30 minutes, and isopropranol was added. DNA was precipitated and washed by 70% ethanol. DNA (8 µg) was then analyzed using 1.2% agarose gel electrophoresis. Annexin V staining was performed after cells were exposed to anoxia with a commercially available kit according to the protocols of the manufacturer (Roche).
Electroimmunoblotting
The details are provided in the online data supplement.
Induction of MI and BMSC Therapy
Myocardial infarction was created in wild-type C57B6 mice by permanent ligation of left anterior descending coronary artery (LAD). The animals were anesthetized with sodium pentobarbital (50 mg/kg IP) and mechanically ventilated. After a left-sided minithoracotomy, the heart was exposed and LAD was ligated by 7-0 ethicon suture at just below the atrioventricular border. The mice were then randomly given an intraventricular injection with a 31-gauge needle of one of the following: 100 µL of DMEM (G-1), 1x106 BMSCs/100 µL (G-2), or 1x106 anoxic preconditioning (AP)-BMSCs/100 µL (G-3). Cultured BMSCs used for injection were taken from green fluorescent protein (GFP) transgenic mice. AP-BMSCs were exposed to 4 hours of anoxia followed by incubation in oxygenated medium for 2 hours. Exposure of BMSCs to anoxia for 4 hours did not cause irreversible damage. The chest was closed, and animals were weaned from the ventilator and allowed to recover.
Echocardiography
Mouse heart function was assessed by transthoracic echocardiography, which was performed at fifth day and 4 weeks after MI using HDI 5000 SonoCT (Phillips) with a 15-MHz probe. Details are given in the online data supplement.
Infarct Size and Infarct Wall Thickness Measurement
After echocardiographic measurements, the animals were euthanized and the hearts removed. The excised heart was cut into 3 transverse slices. Each slice was fixed in 4% paraformaldehyde and embedded in paraffin or frozen in optimal cutting temperature (OCT) compound. Sections (5-µm thick) were mounted on microscopic glass slides. Middle transverse section was stained with hematoxylin–eosin and Masson’s trichrome for both infarct size and wall thickness measurements. Infarct size was defined as the sum of the epicardial and endocardial infarct circumference divided by the sum of the total LV epicardial and endocardial circumferences using computer-based planimetry. The mean wall thickness of infarcted myocardium was measured from 3 equidistant points. Quantitative assessment of each parameter was performed with the use of image analysis software (version 1.6065; NIH).
Immunohistochemical Evaluation
To evaluate blood vessel density and Ki-67–positive cardiomyocytes, the immunoperoxidase method was used. Serial paraffin heart sections were deparaffinized. Endogenous peroxidase activity was blocked by 3% H2O2 for 20 minutes. The sections were incubated with antibodies specific to Ki-67 (DAKO), 
–smooth muscle actin (-SMA) (Sigma), von Willebrand factor (vWF) (DAKO), and platelet endothelial cell adhesion molecule (PECAM)-1 (Santa Cruz Biotechnology) at room temperature for 1 hour. Then, the sections were treated with a biotinylated appropriate secondary antibody followed by incubation with avidin horseradish peroxidase complex (ABC method; Vector Labs). Finally, the sections were colored with diaminobenzidine. Blood vessel density in infarcted myocardium was calculated in at least 8 randomly high-power fields on each heart section.
For detecting GFP-positive cardiomyocytes and vessels, fluorescent immunostaining for vWF, -SMA, -sarcomeric actin, and desmin (Sigma) were performed. The heart section slides were incubated with goat serum for 20 minutes at room temperature. Then samples were incubated with primary antibodies and treated with respective secondary antibodies that conjugated with Alexa Fluor 546 or Alexa Fluor 633. Nuclei were stained with 4',6-diamino-2-phenylindole (DAPI) when necessary. Fluorescent images were obtained with an Olympus BX 41 microscope equipped with digital camera (Olympus) and Leitz DMRBE fluorescence microscopic equipped with a TCS 4D confocal scanning attachment (Leica Inc).
TUNEL Analysis
Apoptotic myocytes after MI were evaluated by TUNEL assay in serial paraffin and cryosections with an ApopTag kit (Chemicon). More than 20 tissue sections in each group were examined microscopically. Four fields each were selected in noninfarction and border areas. The percentage of apoptotic cardiomyocyte was termed the apoptotic index.
Statistical Analysis
Data were expressed as mean±SEM. For the comparison of in vitro data, ultrasound parameters, and histological data, an ANOVA means table with Fisher’s post hoc test was used for continuous data. For the comparison of GFP+ cell number, the unpaired Student’s t test was used. Mann–Whitney U test was performed for nonparametric continuous data (the number of GFP+ cardiomyocytes). Differences with a value of P<0.05 were regarded as statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Survival Gene and Transcription Factor Expression in BMSCs Subjected to Anoxia
Typical BMSCs in primary culture are illustrated in Figure 1A. Fluorescence-activated cell sorting demonstrated that BMSCs expressed high levels of c-kit (>85%) and sca-1 (>95%). Expression of CD34, VE-cadherin, and Flk-1 ranged from 31% to 44% of the total population, which was in agreement with previously published data (Figure 1B).12 Therefore, isolated BMSCs comprised mostly mesenchymal stem cells.
|
Akt activity was determined in BMSCs before and after subjecting them to anoxia. Representative Western blots of Akt are illustrated in Figure 2A. Activation of Akt survival gene was strongly increased in BMSCs following anoxia, and phospho-Akt level of BMSCs was increased many folds after anoxia (arbitrary units, 1517±149 in 2 hours of anoxia, P<0.05; 3647±816 in 4 hours of anoxia, P<0.01; 1983±329 in 6 hours of anoxia, P<0.05; versus 670±112 in 0 hour anoxia, respectively). Phospho–endothelial NO synthase (eNOS) level was also increased in BMSCs following anoxia (Figure 2B).
|
P<0.01 vs 0-hour control. C, GATA-4 and MEF-2C were insignificantly increased in BMSCs following anoxia.Our laboratory previously reported that the expression of cardiomyocyte transcription factors such as GATA-4 and MEF-2C was important in transdifferentiation of BMSCs into cardiomyocytes.12 Therefore, we next examined whether these factors were upregulated in BMSCs following anoxia. Western blot analysis showed that the expression of GATA-4 in BMSCs was slightly increased after anoxia, but the expression of MEF-2C was not increased following anoxia (Figure 2C).
BMSCs Prevent Cardiomyocyte Apoptosis Induced by Anoxia
It has been reported that Akt is involved in antiapoptotic signaling.13 Therefore, we examined the antiapoptotic effect of BMSCs. DNA fragmentation was assessed in cultured cells with or without being exposed to anoxia. Cardiomyocytes after 3 hours of anoxia displayed the typical nucleosome spacing ladder that is indicative of apoptosis (Figure 3A). The DNA laddering was not observed in normal cardiomyocytes and in BMSCs after 4 hours of anoxia (Figure 3B). When cardiomyocytes were cultured with BMSCs in a ratio of 10:1 and exposed to 3 hours of anoxia, DNA fragmentation was diminished (Figure 3C). Annexin V staining showed that the percentage of apoptotic cardiomyocytes was reduced (P<0.01) in cocultured cells exposed to anoxia for 3 hours compared with cardiomyocytes alone (Figure 3D).
|
To explore the mechanism of protection, we next examined Akt activity in cardiomyocytes alone or in cardiomyocytes cocultured with BMSCs (Figure 3E and 3F). For coculture experiments, BMSCs and cardiomyocytes were cultured in 2 individual chambers separated by a semipermeable membrane (3-µm hole). This system allowed sharing the culture medium in 2 chambers but prevented cells contacts. Phosho-Akt level peaked in cardiomyocytes after 2 hours of anoxia but was decreased to very low levels after 4 hours of anoxia (arbitrary units, 2283±350 in 2 hours of anoxia, P<0.01; 962±243 in 4 hours of anoxia, 561±90 in 6 hours of anoxia, versus 940±230 in 0 hour of anoxia, respectively). However, the phosphorylation of Akt in cardiomyocytes cocultured with BMSC was significantly increased after 4 hours of anoxia (arbitrary units, 2685±268 in 2 hours, P<0.01; 2320±673 in 4 hours, P<0.01; 988±498 in 6 hours; versus 820±121 in 0 hour, respectively).
Secretion of Cytokines by BMSCs
Recently, it has been reported that BMSCs secrete a wide array of cytokines that exert beneficial effects on surrounding cells.14,15 We, therefore, examined the level of cytokines in either BMSC-conditioned medium (BM-M) or cardiomyocyte-conditioned medium (CM-M) with or without exposure to anoxia for 4 hours (Figure 4). Under normoxic conditions, vascular endothelial growth factor (VEGF) (8.14±0.70 pg/µg protein from BM-M versus 1.44±0.34 pg/µg protein from CM-M, P<0.05), basic fibroblast growth factor (bFGF) (32.4±4.0 versus 7.1±3.1, P<0.05), insulin-like growth factor (IGF) (81.0±15.7 versus 10.5±1.2, P<0.05), and stromal cell–derived factor (SDF) (0.13±0.01 versus 0.02±0.01, P<0.05) in BM-M were significantly higher compared with CM-M. After 4 hours of anoxia, these proteins were increased by 30% to 150% in BM-M. After anoxia, only VEGF and SDF were increased in CM-M with no change in bFGF. In contrast, EGF was decreased by 65%.
|
Recruited BMSCs to the Injured Myocardium Protect Cardiomyocytes in Early Phase of MI
Five mice in each group were examined for cardiac function by echocardiography at 5 days and were then euthanized. Immunofluoresent staining revealed that GFP-positive cells were immediately recruited after coronary ligation to the injured myocardium in both G-2 and G-3 animals (Figure 5). The number of GFP-positive cells per field was higher in G-3 than in G-2 (54.1±9.9 versus 45.4±7.9, P<0.05). Our in vitro results suggested that the protective effects of BMSCs were attributable, in part, to reduction of cardiomyocyte apoptosis. To determine whether the recruited BMSCs mediated the antiapoptotic effects in the ischemic myocardium, TUNEL labeling was performed. The results showed that the number of TUNEL-positive cells in the periinfarct region was significantly different among the 3 groups (Figure 6). Apoptotic cardiomyocyte index was significantly reduced in G-2 and G-3 (8.0±0.74 in G-2, P<0.05, and 4.1±1.1 in G-3, P<0.01, versus 11.1±3.4 in G-1, respectively).
|
|
Heart function and hemodynamic parameters on day 5 were almost similar among the 3 groups. Initial infarct size on day 5 was also similar among the 3 groups.
Improvement of Cardiac Function and Cardiac Morphology in Chronic Phase of MI
LV internal dimension at both diastole and systole were significantly smaller in G-3 animals compared with both G-1 and G-2 animals 4 weeks after MI. Percent fractional shortening and left ventricular ejection fraction were also significantly higher in G-3 animals. G-2 animals had better left ventricular ejection fraction compared with G-1 (supplemental Table I). The percentage of infarct area was significantly reduced in G-3 (34.5±4.8%) compared with G-1 (43.3±4.5%; P<0.01) and G-2 (40.4±5.0%; P<0.05) (Figure 7D). In G-3 animals, the cell structure was better preserved in the infarct area. The LV infarct wall was thicker in G-3 (0.38±0.10 mm) compared with G-1 (0.29±0.05 mm; P<0.05) (Figure 7E).
|
Regeneration of Cardiomyocytes and Angiogenesis by BMSCs
GFP-positive cells were observed in the hearts of both G-2 and G-3 mice. Interestingly, they were mostly localized in the border area. However, the frequency of GFP-positive cardiomyocytes was very low in both G-2 and G-3 (3.8±1.7 cells/4x104 cardiomyocytes in G-2 and 4.3±1.5 cells/4x104 cardiomyocytes in G-3) (Figure 8A and 8B). Immunostaining for Ki-67 was used to determine cycling cells in the myocardium after MI. The percentage of Ki-67–positive cardiomyocytes was similar among the 3 groups (0.70±0.34% in G-1, 0.76±0.22% in G-2, and 0.95±0.30% in G-3).
|
P<0.005. Bar scale=20 µm.PECAM-1 was used as a marker for endothelial cells (Figure 8C through 8E). The mean number of microvessels per randomly chosen field did not differ between G-2 and G-3 mice (146.8±20.4 in G-2 and 155.9±23.6 in G-3), but it was increased 1.5-fold in both G-2 and G-3 compared with G-1 animals (101.0±20.3, P<0.01) (Figure 8F).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
BMSCs are multipotent and can differentiate into several distinct cell types, including cardiac cell components, within the microenvironment of the heart.4,16 There appears to be general agreement that BMSCs therapy has potential to improve perfusion and contractile performance of the injured heart.4–9 However, accumulating evidence has questioned these previous reports.5,17 The mechanism underlying this therapeutic effect has not been clearly defined, with an intense debate over differentiation versus fusion,4,18 and it appears to be far more complex than previously anticipated. Recently, it has been reported that BMSCs provide protection by paracrine mechanisms involving release of a wide array of cytokines that exert their effects on surrounding cells.14,15 We, therefore, hypothesized that BMSCs mediate their protection by paracrine mechanism under ischemic conditions and that preconditioning of BMSCs strongly enhances their survival and regenerative capacity. We have demonstrated here that (1) BMSCs showed strong upregulation of the cell survival gene Akt following brief anoxia. BMSCs prevented apoptosis in cardiomyocytes exposed to anoxia after coculture. Cardiac transcription factors such as GATA-4 and MEF-2C were not markedly upregulated after anoxia. (2) Recruited BMSCs following MI exerted a marked inhibitory effect on LV remodeling through paracrine mediators, which were released by BMSCs.
Our in vitro results showed that Akt activity in BMSCs was significantly increased following anoxia. Akt activity in cardiomyocytes peaked after 2 hours of anoxia and decreased after 4 hours of anoxia. However, under coculture conditions, Akt activity in cardiomyocytes was persistently increased after 4 hours of anoxia. Thus, apoptosis was prevented in ischemic cardiomyocytes as a result of Akt upregulation. This antiapoptotic effect was dependent on the severity of ischemia. Apoptosis was observed in cardiomyocytes subjected to hypoxia for 48 to 72 hours, but it was completely abolished in cardiomyocytes cocultured with BMSCs (data not shown). We found that the underlying mechanism of the cardiomyocyte protection exerted by BMSCs was via activation of Akt survival pathway under ischemia. The serine/threonine protein kinase Akt was first identified as an oncogene owing to its ability to transform normal cells.19 Subsequent studies, however, demonstrated that Akt functioned as an antiapoptotic protein, protecting cells against death induced by growth factor withdrawal.20,21 Akt acts by targeting apoptotic family members Ced9/bcl2 and Ced-3 caspases, forkhead, and transcription factors. In addition, it also modulates intracellular glucose metabolism, thereby enhancing energy production during hypoxia.22 More recently, an extended role for Akt has been established in a variety of cardiovascular events.23 Constitutive activation of Akt signaling has been shown to minimize cardiomyocyte apoptosis in vivo after ischemia–reperfusion injury,24,25 and Akt activation has been shown to preserve the function of hypoxic cardiomyocytes at levels comparable to those of normoxic controls.25
An earlier study reported that ex vivo hypoxia in BMSCs stimulated the synthesis of vascular endothelial cell growth factor mRNA, resulting in differentiation of BMSCs into endothelial cells in ischemic hindlimb.26 It suggests that BMSCs also comprise a population of endothelial progenitor cells (EPC). However, transcription factors such as GATA-4 and MEF-2C were insignificantly increased in BMSCs following ischemia. Although BMSCs were isolated by Dexter’s method, which excluded hematopoietic cells, they were positive for several phenotype markers. The precise nature of the bone marrow–derived cardiomyocyte precursor cells remains unknown, although the majority of isolated BMSCs might contain primarily nonmyogenic cells.
Our data further showed that anoxic preconditioning (AP) of BMSCs increased their effectiveness against ischemic injury by reducing cell apoptosis and LV remodeling. Ischemic preconditioning is known to promote synthesis of several proteins that enhance cell survival.27 Following AP, BMSCs expressed increased level of Akt and eNOS phosphorylation. Thus, these cells were able to survive better in ischemic environment and enhance their therapeutic potential. Several studies clearly indicate that NO plays an important role in cardioprotection against ischemic injury. Chronic hypoxia increases eNOS expression and confers resistance to ischemia in cardiomyocytes.28 Ischemic preconditioning protects heart against ischemia–reperfusion injury by increased synthesis of inducible nitric oxide synthase (iNOS).29,30 The protective role of EPC has been shown in a recent study in which ischemic preconditioning mobilized these cells in the ischemic myocardium where they acted as donors of eNOS, iNOS, and VEGF.31 In this study, AP-BMSC therapy significantly reduced infarct size and improved cardiac function. These benefits were mainly associated with reduction of apoptotic cardiomyocytes in periinfarct area. Recently, it has been reported that BMSCs release a wide array of cytokines that directly affect surrounding cells.15,16 Akt and possibly other cell survival pathways may be rapidly activated by AP-BMSCs in vivo model. Involvement of protective proteins may result in overall improvement of cardiac function caused by prevention of cardiomyocytes apoptosis and preservation of ischemic cardiomyocytes function. The cumulative effects resulted in attenuation of LV remodeling after MI.
LV remodeling is an important process affecting ventricular function and progression of cardiac failure1 and is characterized by an increase in myocardial mass associated with cardiomyocyte hypertrophy. There is evidence that pathological remodeling also involves the death of cardiomyocytes by apoptosis.2 The relative lack of oxygen to the hypertrophied cardiomyocytes might be an important etiological factor in their programmed death. Several studies have implicated cardiomyocyte apoptosis as the underlying mechanism responsible for LV remodeling after MI.32,33
Although BMSCs could differentiate into cardiomyocytes and vascular cells, thereby contributing to regeneration of myocardium4 and angiogenesis10,11 in ischemic hearts, recent evidence has questioned the role of BMSCs in cardiac regeneration.5,17 In our in vivo experiments, functioning cardiac fibers developed from GFP+ cells could not be found on a large scale. The frequency of the BMSC-derived cardiomyocytes was very small. Our in vitro results also showed that cardiac transcription factors such as GATA-4 and MEF-2C were insignificantly increased in BMSCs following anoxia. These results support the concept that AP-BMSC therapy improves cardiac function, which is mediated by paracrine factors rather than myogenesis. Previous work has held the notion that the adult heart is terminally differentiated organ without self-renewal potential. However, recent studies have challenged these preexisting notions regarding cardiac regeneration and have identified resident stem/progenitor cell population capable of self-differentiation into cardiomyocytes in adult heart.34–37 Furthermore, it has been reported that FGF-2 could regulate the fate and cardiogenic conversion of undifferentiated progenitors.38 In addition to the reduction of apoptotic cardiomyocytes, AP-BMSC therapy might act in a supportive paracrine manner that stimulates the mobilization and growth of resident cardiac stem cells, resulting in infarct size reduction.
Ischemic preconditioning is such a powerful stimulus for cardioprotection that no other therapeutic approach has matched its effect. Diverse signaling pathways have been involved in ischemic preconditioning. The latter phase of this protection is believed to be attributable to synthesis or secretion of proteins.27 Similarly, BMSCs also respond to ischemic preconditioning stimuli and become tolerant to lethal ischemia (unpublished data, 2006). Furthermore, recent reports have shown that cytokine-preconditioned adult stem cells can differentiate into large numbers of cardiomyogenic cells in vivo and in vitro.39,40 During preconditioning, BMSCs upregulate several cytokines, growth factors, and survival protein and are secreted in the immediate environment. These serve as antiapoptotic and myoangiogenic differentiation stimulants. Besides numerous benefits bestowed by preconditioning, the direct injection of preconditioned cells can be reduced because of their enhanced survival rate and perhaps higher potential for regeneration. Therefore, preconditioning appears to be an exciting and innovative approach in cell-based therapy.
Conclusion
Our results show that BMSCs exert their protective effects via upregulation of Akt and eNOS under ischemic conditions, thus preventing cardiomyocyte apoptosis. Preconditioning of BMSCs enhances their survival and ability to attenuate LV remodeling after MI by preventing cardiomyocyte apoptosis through paracrine mediators.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grants R37-HL074272, HL023597, HL080686 (to M.A.) and HL 083236 (to M.X.).
|
Footnotes |
|---|
*Both authors contributed equally to this study.
Original received December 14, 2005; revision received April 25, 2006; accepted May 1, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81: 1161–1172.[Medline] [Order article via Infotrieve]
2. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997; 80: 15L–25L.[CrossRef][Medline] [Order article via Infotrieve]
3. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodel MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001; 107: 1395–1402.[CrossRef][Medline] [Order article via Infotrieve]
4. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701–705.[CrossRef][Medline] [Order article via Infotrieve]
5. Balsam LB, Wagners AJ, Christensen JL, Kofidls T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428: 668–673.[CrossRef][Medline] [Order article via Infotrieve]
6. Kudo M, Wang Y, Wani M, Ayub A, Ashraf M. Implantation of bone marrow reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol. 2003; 35: 1113–1119.[CrossRef][Medline] [Order article via Infotrieve]
7. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow transplantation in humans. Circulation. 2002; 106: 1913–1918.
8. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schachinger V, Dimmeler S, Zeiher AM. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI). Mechanistic insight from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003; 108: 2212–2218.
9. Chen S, Fang W, Ye F, Liu YH, Qian J, Shan S, Zhang J, Chunhua RZ, Liao L, Lin S, Sun J. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004; 94: 92–95.[CrossRef][Medline] [Order article via Infotrieve]
10. Kocher AA, Szabolcs SM-J, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NW, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001; 7: 430–436.[CrossRef][Medline] [Order article via Infotrieve]
11. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi J, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001; 103: 634–637.
12. Xu M, Wani M, Dai YS, Wang J, Yan M, Ayub A, Ashraf M. Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation. 2004; 110: 2658–2665.
13. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997; 88: 434–437.
14. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004; 109: 1543–1549.
15. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11: 367–368.[CrossRef][Medline] [Order article via Infotrieve]
16. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseleby AB, Deans R, Marshak DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000; 6: 1282–1286.[CrossRef][Medline] [Order article via Infotrieve]
17. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428: 664–668.[CrossRef][Medline] [Order article via Infotrieve]
18. Nyglen JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, Taneera J, Fleischmann BK, Jacobsen SE-W. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004; 10: 494–501.[CrossRef][Medline] [Order article via Infotrieve]
19. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997; 276: 1848–1850.
20. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidyliositol-3,4-bisphosphate. Science. 1997; 275: 665–668.
21. Ulrich E, Duwel A, Kauffmann-zeh A, Gilbert C, Lyon D, Rudkin B, Evan G, Marrtin-Zanca D. Specific TrkA survival signals interfere with different apoptotic pathways. Oncogene. 1998; 16: 825–832.[CrossRef][Medline] [Order article via Infotrieve]
22. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13: 2905–2927.
23. Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res. 2000; 86: 4–5.
24. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000; 101: 660–667.
25. Matsui T, Tao J, Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001; 104: 330–335.
26. Li T-S, Hamano K, Suzuki K, Ito H, Zempo N, Matsuzaki M. Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rat. Am J Physiol Heart Circ Physiol. 2002; 283: H468–H473.
27. Wang Y, Haider H-Kh, Ashraf M. Mechanisms by which K(ATP) channel openers produce acute and delayed cardioprotection. Vascul Pharmacol. 2005; 42: 253–264.[CrossRef][Medline] [Order article via Infotrieve]
28. Shi Y, Baker JE, Zhang C, Tweddel JS, Su J, Pritchard KA. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heart shock protein 90 association and serine phosphorylation. Circ Res. 2002; 91: 300–306.
29. Bolli R, Zughaib M, Li XY, Tang XL, Sun JZ, Triana JF, McCay PB. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function: a pathophysiological basis for chronic myocardial "stunning". J Clin Invest. 1995; 96: 1066–1084.[Medline] [Order article via Infotrieve]
30. Guo Y, Jones W, Xuan XT, Tang XL, Bao W, Wu WJ, Han H, Lauback V, Ping P, Yang Z, Qin Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A. 1999; 96: 11507–11512.
31. Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T, Losordo DW. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation. 2005; 111: 1114–1120.
32. Olivetti G, Quaini F, Sala R, Lagrasta C, Corradi D, Bonacina E, Gambert SR, Cigola E, Anversa P. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol. 1996; 28: 2005–2016.[CrossRef][Medline] [Order article via Infotrieve]
33. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation. 1997; 95: 320–323.
34. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763–776.[CrossRef][Medline] [Order article via Infotrieve]
35. Messina E, Angelis LD, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, Cossu G, Giacomello A. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95: 911–921.
36. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, Colucci WS, Liao R. CD 31– but not CD 31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res. 2005; 97: 52–61.
37. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, Torella D, Tang XL, Rezazadeh A, Kajstura J, Leri A, Hunt G, Varma J, Prabhu SD, Anversa P, Bolli R. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A. 2005; 102: 3766–3771.
38. Rosenblatt-Velin N, Lepore MG, Cartoni C, Beermann F, Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest. 2005; 115: 1724–1733.[CrossRef][Medline] [Order article via Infotrieve]
39. Shmelkov SV, Meeus S, Moussazadeh N, Kermani P, Rashbaum WK, Rabbany SY, Hanson MA, Lane WJ, Clair RS, Walsh KA, Dias S, Jacobson JT, Hempstead BL, Edelberg JM, Rafii S. Cytokine preconditioning promotes codifferentiation of human fatal liver CD133+ stem cells into angiomyogenic tissue. Circulation. 2005; 111: 1175–1183.
40. Li TS, Hayashi M, Ito H, Furutani A, Murata T, Matsuzaki M, Hamano K. Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-ß-preprogrammed bone marrow stem cells. Circulation. 2005; 111: 2438–2445.
This article has been cited by other articles:
 |
|
 |
|
  Y. Wang, X.-C. Liu, G.-W. Zhang, J. Zhao, J.-M. Zhang, R.-F. Shi, Y.-Z. Huang, C.-H. Zhao, T.-J. Liu, C.-X. Song, et al. A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction Cardiovasc Res, December 1, 2009; 84(3): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fan, C. Lin, S. Zhuo, L. Chen, N. Liu, Y. Luo, J. Fang, Z. Huang, Y. Lin, and J. Chen Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction Eur J Heart Fail, November 1, 2009; 11(11): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, J. Tan, Y. Wang, K. K. Meldrum, C. A. Dinarello, and D. R. Meldrum IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction PNAS, October 13, 2009; 106(41): 17499 - 17504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Lai, K.-L. Ang, W. Rathbone, N. J. Harvey, and M. Galinanes Randomized controlled trial on the cardioprotective effect of bone marrow cells in patients undergoing coronary bypass graft surgery Eur. Heart J., October 1, 2009; 30(19): 2354 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei, G. S. Feigenbaum, J. E. Rodriguez, D. Valdes, P. M. Pattany, J. P. Zambrano, Q. Hu, I. McNiece, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity PNAS, August 18, 2009; 106(33): 14022 - 14027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Boudoulas and A. K. Hatzopoulos Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease Dis. Model. Mech., July 1, 2009; 2(7-8): 344 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, J. Tan, A. Coffey, J. Fehrenbacher, B. R. Weil, and D. R. Meldrum Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1{alpha} mediates estrogen receptor-{alpha}-induced mesenchymal stem cell vascular endothelial growth factor production J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Weil, A. M. Abarbanell, J. L. Herrmann, Y. Wang, and D. R. Meldrum High glucose concentration in cell culture medium does not acutely affect human mesenchymal stem cell growth factor production or proliferation Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1735 - R1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shabbir, D. Zisa, G. Suzuki, and T. Lee Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1888 - H1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu, H. K. Haider, S. Jiang, and M. Ashraf Sca-1+ Stem Cell Survival and Engraftment in the Infarcted Heart: Dual Role for Preconditioning-Induced Connexin-43 Circulation, May 19, 2009; 119(19): 2587 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hamdi, A. Furuta, V. Bellamy, A. Bel, E. Puymirat, S. Peyrard, O. Agbulut, and P. Menasche Cell Delivery: Intramyocardial Injections or Epicardial Deposition? A Head-to-Head Comparison Ann. Thorac. Surg., April 1, 2009; 87(4): 1196 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, M. A. Stagg, S. Fukushima, G. K. R. Soppa, U. Siedlecka, S. J. Youssef, K. Suzuki, M. H. Yacoub, and C. M. N. Terracciano Adult progenitor cell transplantation influences contractile performance and calcium handling of recipient cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H927 - H936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. U. Schraufstatter, R. G. DiScipio, M. Zhao, and S. K. Khaldoyanidi C3a and C5a Are Chemotactic Factors for Human Mesenchymal Stem Cells, Which Cause Prolonged ERK1/2 Phosphorylation J. Immunol., March 15, 2009; 182(6): 3827 - 3836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Zeller, Y. Wang, T. A. Markel, B. Weil, A. Abarbanell, J. L. Herrmann, M. L. Kelly, A. Coffey, and D. R. Meldrum Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection. Ann. Thorac. Surg., March 1, 2009; 87(3): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Korf-Klingebiel, T. Kempf, T. Sauer, E. Brinkmann, P. Fischer, G. P. Meyer, A. Ganser, H. Drexler, and K. C. Wollert Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction Eur. Heart J., December 1, 2008; 29(23): 2851 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Markel, Y. Wang, J. L. Herrmann, P. R. Crisostomo, M. Wang, N. M. Novotny, C. M. Herring, J. Tan, T. Lahm, and D. R. Meldrum VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2308 - H2314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gnecchi, Z. Zhang, A. Ni, and V. J. Dzau Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy Circ. Res., November 21, 2008; 103(11): 1204 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Haider, S. Jiang, N. M. Idris, and M. Ashraf IGF-1-Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell Mobilization via Paracrine Activation of SDF-1{alpha}/CXCR4 Signaling to Promote Myocardial Repair Circ. Res., November 21, 2008; 103(11): 1300 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, P. R. Crisostomo, M. Wang, T. A. Markel, N. M. Novotny, and D. R. Meldrum TGF-{alpha} increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1115 - R1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Markel, P. R. Crisostomo, M. Wang, Y. Wang, T. Lahm, N. M. Novotny, J. Tan, and D. R. Meldrum TNFR1 signaling resistance associated with female stem cell cytokine production is independent of TNFR2-mediated pathways Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1124 - R1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Crisostomo, A. M. Abarbanell, M. Wang, T. Lahm, Y. Wang, and D. R. Meldrum Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1726 - H1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Coppen, S. Fukushima, Y. Shintani, K. Takahashi, A. Varela-Carver, H. Salem, K. Yashiro, M. H. Yacoub, and K. Suzuki A Factor Underlying Late-Phase Arrhythmogenicity After Cell Therapy to the Heart: Global Downregulation of Connexin43 in the Host Myocardium After Skeletal Myoblast Transplantation Circulation, September 30, 2008; 118(14_suppl_1): S138 - S144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Liebler, C. Lutzko, A. Banfalvi, D. Senadheera, N. Aghamohammadi, E. D. Crandall, and Z. Borok Retention of human bone marrow-derived cells in murine lungs following bleomycin-induced lung injury Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L285 - L292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Carr, D. J. Stuckey, L. Tatton, D. J. Tyler, S. J. M. Hale, D. Sweeney, J. E. Schneider, E. Martin-Rendon, G. K. Radda, S. E. Harding, et al. Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H533 - H542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Bishopric Mesenchymal Stem Cell-Derived IL-10 and Recovery From Infarction: A Third Pitch for the Chord Circ. Res., July 18, 2008; 103(2): 125 - 127. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Burchfield, M. Iwasaki, M. Koyanagi, C. Urbich, N. Rosenthal, A. M. Zeiher, and S. Dimmeler Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction Circ. Res., July 18, 2008; 103(2): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ray, C. M. Herring, T. A. Markel, P. R. Crisostomo, M. Wang, B. Weil, T. Lahm, and D. R. Meldrum Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1498 - R1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Markel, M. Wang, P. R. Crisostomo, M. C. Manukyan, J. A. Poynter, and D. R. Meldrum Neonatal stem cells exhibit specific characteristics in function, proliferation, and cellular signaling that distinguish them from their adult counterparts Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1491 - R1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Hu, S. P. Yu, J. L. Fraser, Z. Lu, M. E. Ogle, J.-A. Wang, and L. Wei Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 799 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Crisostomo, Y. Wang, T. A. Markel, M. Wang, T. Lahm, and D. R. Meldrum Human mesenchymal stem cells stimulated by TNF-{alpha}, LPS, or hypoxia produce growth factors by an NF{kappa}B- but not JNK-dependent mechanism Am J Physiol Cell Physiol, March 1, 2008; 294(3): C675 - C682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frantz, D. Vallabhapurapu, J. Tillmanns, N. Brousos, H. Wagner, K. Henig, G. Ertl, A. M. Muller, and J. Bauersachs Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction Eur J Heart Fail, February 1, 2008; 10(2): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dimmeler, J. Burchfield, and A. M. Zeiher Cell-Based Therapy of Myocardial Infarction Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shujia, H. K. Haider, N. M. Idris, G. Lu, and M. Ashraf Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair Cardiovasc Res, February 1, 2008; 77(3): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Pasha, Y. Wang, R. Sheikh, D. Zhang, T. Zhao, and M. Ashraf Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium Cardiovasc Res, January 1, 2008; 77(1): 134 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J.A. Frost and S. Engelhardt A Secretion Trap Screen in Yeast Identifies Protease Inhibitor 16 as a Novel Antihypertrophic Protein Secreted From the Heart Circulation, October 16, 2007; 116(16): 1768 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Markel, P. R. Crisostomo, M. Wang, C. M. Herring, and D. R. Meldrum Activation of individual tumor necrosis factor receptors differentially affects stem cell growth factor and cytokine production Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G657 - G662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, W. Zhang, P. Crisostomo, T. Markel, K. K. Meldrum, X. Y. Fu, and D. R. Meldrum Sex differences in endothelial STAT3 mediate sex differences in myocardial inflammation Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E872 - E877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M. Winter, R.W. Grauss, B. Hogers, J. van Tuyn, R. van der Geest, H. Lie-Venema, R. V. Steijn, S. Maas, M.C. DeRuiter, A.A.F. deVries, et al. Preservation of Left Ventricular Function and Attenuation of Remodeling After Transplantation of Human Epicardium-Derived Cells Into the Infarcted Mouse Heart Circulation, August 21, 2007; 116(8): 917 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Singla, G. E. Lyons, and T. J. Kamp Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1308 - H1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Wu, B. Zhou, C. T. Yu, B. Cui, S. H. Lu, Z. C. Han, and Y. L. Liu Therapeutic Potential of Human Umbilical Cord Derived Stem Cells in a Rat Myocardial Infarction Model Ann. Thorac. Surg., April 1, 2007; 83(4): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Abraham and G. Gerstenblith Preconditioning Stem Cells for Cardiovascular Disease: An Important Step Forward Circ. Res., March 2, 2007; 100(4): 447 - 449. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Niagara, H. Kh. Haider, S. Jiang, and M. Ashraf Pharmacologically Preconditioned Skeletal Myoblasts Are Resistant to Oxidative Stress and Promote Angiomyogenesis via Release of Paracrine Factors in the Infarcted Heart Circ. Res., March 2, 2007; 100(4): 545 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Wu, Y. L. Liu, B. Zhou, and Z. C. Han Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 770 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jiang, H. Kh. Haider, N. M. Idris, A. Salim, and M. Ashraf Supportive Interaction Between Cell Survival Signaling and Angiocompetent Factors Enhances Donor Cell Survival and Promotes Angiomyogenesis for Cardiac Repair Circ. Res., September 29, 2006; 99(7): 776 - 784. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||